ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Wang, Zhenwei; Dai, Zhihong; Wang, Bingwei; Gao, Yuren; Gao, Xiang; Wang, Liang; Zhou, Sihai; Yang, Liqin; Qiu, Xiaofu; Liu, Zhiyu*南方医科大学
OncoTargets and Therapy2021DOI: 10.2147/OTT.S291267
3被引5阅读
引用收藏
分享

摘要

Purpose: Prostate cancer is the second leading cause of cancer death in men worldwide. Olaparib is clinically approved for the treatment prostate cancer, but cytotoxicity and off-target effects including DNA damage limit its clinical applications. In the current study, new strategies to improve the therapeutic efficacy of olaparib for the treatment of prostate cancer were investigated. @@@ Methods: Two prostate cancer cell lines were exposed to the c-MET inhibitor PHA665752 and/or the PARP inhibitor olaparib. Cell counting kit-8, colony formation assays, and transwell assays were conducted to evaluate the cytotoxicity of olaparib alone or in combination with PHA665752 in prostate cancer cell lines. Western blotting, immunofluorescence staining, and the comet assay were used to assess the effects of PHA665752 on olaparib-induced DNA damage. @@@ Results: Combined inhibition of c-MET and PARP resulted in effective and synergistic blocking of the growth of prostate cancer cell lines. Invasion and migration were significantly suppressed when the agents were combined. Mechanistically, dual blocking of PARP and c-MET in prostate cancer cell lines was associated with an impaired DNA damage response. Interestingly, immunofluorescence staining analysis of RAD51 protein indicated that the c-MET inhibitor PHA665752 significantly impaired homologous repair via down-regulated translocation of RAD51 into the nucleus in prostate cancer cells. @@@ Conclusion: The combination of the c-MET inhibitor PHA665752 and the PARP inhibitor olaparib may be a promising therapeutic strategy in patients with prostate cancer.

学科与关键词

关键词
combination therapyPARP inhibitorPHA665752prostate cancer
相关
加载中…
  • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
  • The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation
    Kuang, Qiwen; Liang, Yuxiang; Zhuo, Yangjia; Cai, Zhiduan; Jiang, Funeng; Xie, Jianjiang; Zheng, Yu; Zhong, Weide*OncoTargets and Therapy, 2021, 14: 3353-3366.被引 8
  • Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer
    Li, Jianhua; Wu, Huanxian; Lv, Shidong; Quan, Dongling; Yang, Danni; Xu, Jiahuan; Chen, Boyu; Ou, Baofang; Wu, Shaoyu*; Wei, Qiang*Die Pharmazie, 2022, 77(2): 59-66.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
OncoTargets and Therapy
发表日期
2021
卷期
第 14 卷
页码
4383-4389
DOI
10.2147/OTT.S291267
语言
ENGLISH
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Science and Technology Planning Project of Guangzhou City, Guangdong, China [201904010035]; Natural Science Foundation of Guangdong Province, China [2018A030313905]; Medical Science Foundation of Dalian, China [2012020]

作者

  • W

    Wang, Zhenwei (第一作者)

    2 · dalian med univ

  • D

    Dai, Zhihong

    2 · dalian med univ

查看全部 10 位作者收起作者
  • W

    Wang, Bingwei

  • G

    Gao, Yuren

    2 · dalian med univ

  • G

    Gao, Xiang

    2 · dalian med univ

  • W

    Wang, Liang

    2 · dalian med univ

  • Z

    Zhou, Sihai

    2 · dalian med univ

  • Y

    Yang, Liqin

    2 · dalian med univ

  • Q

    Qiu, Xiaofu

    2 · southern med univ

  • L

    Liu, Zhiyu (通讯)

    2 · dalian med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417